Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing Read More
Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular Read More
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM – In findings that could eventually Read More
Agendia Announces Study Showing Molecular Subtyping Can Improve Breast Cancer Treatment
IRVINE, CA and AMSTERDAM – In findings that may eventually Read More
Agendia Co-Founder and CSO Develops Method to Identify Women Who Will Benefit from Tamoxifen Therapy for Breast Cancer
IRVINE, CA and AMSTERDAM, July 31, 2014 – Innovative research Read More
Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 Read More
Value of Breast Cancer Molecular Subtyping Documented by Independent Study Comparing Genomic Tests at ASCO 2014 Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 10, 2014 – Read More
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New Read More
Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports
Presentations to American Society of Breast Surgeons Detail Clinical Insights Read More
